Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Daniel Perkins(The University of Melbourne), David Castle(University of Tasmania), M.L. Williams(Monash University), Jerome Sarris(The University of Melbourne), Paul Liknaitzky(Monash University), Nicole Leite Galvão‐Coelho(Universidade Federal do Rio Grande do Norte), Sean Hood(The University of Western Australia), Christopher G. Davey(The University of Melbourne), Olivia Carter(The University of Melbourne), Yvonne Bonomo, Susan L. Rossell(St Vincent's Hospital Melbourne), Michael Berk(The Royal Melbourne Hospital), David Forbes(The University of Melbourne), Greg Murray(Hope College), Violeta Schubert(The University of Melbourne), Daniël Hoyer(Complexity Science Hub), Meaghen O’Donnell(The University of Melbourne), Dan Siskind(Metro South Health), David Penington(The University of Melbourne), Colleen Loo(Black Dog Institute)
Cited by 54
Related Papers
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
|The Lancet Psychiatry|2019|1.5k
So depression is an inflammatory disease, but where does the inflammation come from?
|BMC Medicine|2013|1.4k
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013
|Bipolar Disorders|2012|1.2k
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k